Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Inclusion Criteria: * Diagnosed with Hypertrophic Cardiomyopathy with a left ventricular wall thickness greater than or equal to 13mm as determined by the echocardiogram obtained during the screening/baseline period * Left ventricular ejection fraction (LVEF) greater than or equal to 50% as determined by echocardiogram obtained during the screening/baseline period * Symptoms consistent with New York Heart Association (NYHA) Class II-III heart failure by physician assessment, or asymptomatic/NYHA Class I patients with: * NT-proBNP blood sample levels above 250 pg/ml and * peak VO2 of less than or equal to 80% of predicted based on age and gender as determined by cardiopulmonary exercise testing Exclusion Criteria: * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for ≥7 days after stopping study drug * Patients with a resting or provokable left ventricular outflow tract gradient of greater than or equal to 30mm Hg * Septal reduction procedure within 3 months of the screening/baseline visit * History of atrial fibrillation within 6 months of the screening/baseline visit or placement of ICD for secondary prevention * Patients with a peak VO2 on the screening/baseline cardiopulmonary exercise test of \> 80% of predicted based on age and gender * Patients who require treatment with ACE inhibitors, angiotensin receptor blockers (ARBs), or renin inhibitors * Known infiltrative or storage disorder such as Fabry disease, or amyloidosis * Known or suspected symptomatic coronary artery diseases or evidence of prior myocardial infarction * Systolic blood pressure of \<100 mmHg or symptomatic hypotension during the screening/baseline period or treatment run-in period * Contraindication to ARB administration or prior history of angioedema * Persistent uncontrolled hypertension